GlassScriptPhysician profile
Kimberly A Cayce
NPI 1659470730
$10,261.18
in general payments reported to CMS, 2019-2025
36 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,919 · 2020: $586 · 2021: $999 · 2022: $695 · 2023: $188 · 2024: $962 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977 · Education: $86.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.89 |
| Education | $86.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,981.84 | 2019-2024 | |
| Abbvie INC. | $654.75 | 2019-2025 | |
| Janssen Biotech, INC. | $503.98 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $467.29 | 2019-2025 | |
| Revance Therapeutics, INC. | $418.52 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $369.63 | 2020-2025 | Blu-U |
| Ucb, INC. | $314.30 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $272.65 | 2019-2025 | Epsolay, Aklief, Oracea |
| Allergan, INC. | $238.74 | 2019-2022 | |
| Lilly USA, LLC | $232.09 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $190.90 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $140.25 | 2019-2024 | |
| Leo Pharma INC. | $138.26 | 2019-2021 | |
| Almirall LLC | $136.77 | 2019-2025 | Seysara, Klisyri |
| Epi Health, LLC | $117.84 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $109.78 | 2019 | |
| Dermavant Sciences, INC. | $106.24 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $105.23 | 2022-2024 | Sotyktu |
| Celgene Corporation | $105.12 | 2019 | |
| Genzyme Corporation | $100.29 | 2020-2024 | |
| Incyte Corporation | $78.24 | 2022-2024 | Opzelura |
| Sandoz INC. | $73.01 | 2019 | |
| Genentech USA, INC. | $67.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.43 | 2024-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $41.19 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $40.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $38.89 | 2021-2024 | Libtayo |
| Dermira, INC. | $36.35 | 2019-2020 | |
| Organogenesis INC. | $19.81 | 2025 | Cygnus Dual |
| Biofrontera INC. | $16.20 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Promius Pharma LLC | $15.79 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $15.30 | 2023 | |
| Mission Pharmacal Company | $15.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.38 | 2020 | |
| Dusa Pharmaceuticals, INC. | $12.95 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cayce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.